Northborough, MA, United States of America

Paul Mcglynn

USPTO Granted Patents = 9 


 

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Paul McGlynn: Innovator in Pharmaceutical Aerosol Products

Introduction

Paul McGlynn is a notable inventor based in Northborough, MA (US), recognized for his contributions to the field of pharmaceutical aerosol products. With a total of nine patents to his name, McGlynn has made significant advancements in the treatment of respiratory diseases, particularly for children.

Latest Patents

Among his latest inventions is a pharmaceutical aerosol product designed for administration by oral or nasal inhalation. This innovative product is particularly aimed at treating respiratory diseases in children. The aerosol composition includes ciclesonide, ethanol, and either 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. This invention showcases McGlynn's commitment to improving healthcare solutions for vulnerable populations.

Career Highlights

Throughout his career, Paul McGlynn has worked with prominent companies in the pharmaceutical industry, including Sunovion Pharmaceuticals Inc. and Covis Pharma GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas, leading to the successful patenting of his inventions.

Collaborations

Some of McGlynn's notable coworkers include Craig R. Abolin and H. Scott Wilkinson. Their collaboration has likely contributed to the successful development of his patented products.

Conclusion

Paul McGlynn stands out as an influential inventor in the pharmaceutical field, particularly in the development of aerosol products for respiratory treatment. His work continues to impact the lives of many, especially children suffering from respiratory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…